Recursion's AI-designed cancer drugs REC-3565 and REC-617 show early clinical promise, with one patient responding unexpectedly well to treatment.

In addition, Rallybio may be eligible to receive certain payments in the event of Recursion’s sale of the REV102 program.

“We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage,” said David Hallett, Chief Scientific Officer of Recursion.

Amid an ongoing housing crisis, state lawmakers are again pushing for Pennsylvania to launch a home repair program to help residents preserve their properties. Identical legislation in the House ...

See our expert dietitian's take on Noom offerings, plus our tester's long-term review as she updates each month.